SG Americas Securities LLC Sells 7,740 Shares of Icon Plc $ICLR

SG Americas Securities LLC decreased its stake in Icon Plc (NASDAQ:ICLR) by 48.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,222 shares of the medical research company’s stock after selling 7,740 shares during the quarter. SG Americas Securities LLC’s holdings in Icon were worth $1,439,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in ICLR. Geneos Wealth Management Inc. lifted its holdings in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares in the last quarter. Spire Wealth Management lifted its stake in shares of Icon by 10.1% during the 3rd quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock valued at $119,000 after buying an additional 62 shares in the last quarter. Mutual Advisors LLC boosted its holdings in Icon by 3.6% in the 2nd quarter. Mutual Advisors LLC now owns 2,698 shares of the medical research company’s stock worth $392,000 after buying an additional 93 shares during the period. Private Trust Co. NA boosted its holdings in Icon by 200.0% in the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after buying an additional 94 shares during the period. Finally, Hunter Perkins Capital Management LLC increased its stake in Icon by 0.4% in the 2nd quarter. Hunter Perkins Capital Management LLC now owns 22,399 shares of the medical research company’s stock worth $3,258,000 after buying an additional 97 shares in the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. TD Cowen decreased their target price on Icon from $183.00 to $172.00 and set a “hold” rating on the stock in a research note on Friday, October 24th. BMO Capital Markets assumed coverage on shares of Icon in a report on Thursday, November 13th. They issued a “market perform” rating and a $175.00 target price on the stock. UBS Group set a $220.00 target price on shares of Icon in a research note on Friday, October 24th. Cowen reiterated a “hold” rating on shares of Icon in a research note on Friday, October 24th. Finally, Leerink Partners reissued an “outperform” rating on shares of Icon in a report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $199.87.

Icon Trading Up 0.0%

Shares of NASDAQ ICLR opened at $182.61 on Friday. Icon Plc has a 1-year low of $125.10 and a 1-year high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The business’s 50 day moving average is $179.24 and its two-hundred day moving average is $174.01. The stock has a market capitalization of $14.75 billion, a P/E ratio of 24.71, a PEG ratio of 3.84 and a beta of 1.26.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.